These proteins share a highly homologous Jumonji C domain endowed with Fe2+ and α‐ketoglutarate for the demethylation of H3K27.1 Overexpression of JMJD3 is correlated with inflammation,2, 3 neurological disorders,4 as well as cancer pathologies5 such as T‐cell acute lymphoblastic leukemia,6 Hodgkin's lymphoma,7 and metastatic prostate cancer.8 It has also been recently shown that JMJD3 can be a new target for pediatric brainstem glioma.9 Because JMJD3 is an inducible enzyme, its suppression could be very attractive for cancer treatment. This evidence concerns the gene KDM6B and brain stem glioma.